skip navigation

Skip Nav

Ensayos clínicos

Ensayos clínicos

A Comparison of Adefovir and Tenofovir for the Treatment of Lamivudine-Resistant Hepatitis B Virus in People With HIV

Patrocinador(es) del estudio: National Institute of Allergy and Infectious Diseases (NIAID)
Números de identificación: NCT00033163, ACTG A5127
  • Concluido

Propósito del estudio

Control of hepatitis B virus (HBV) infection can be difficult in HIV infected people who have taken the antiviral lamivudine (3TC). These people may have HBV that has become resistant to 3TC. Adefovir dipivoxil (ADV) has shown promising anti-HBV activity in clinical trials; tenofovir disoproxil fumarate (TDF) is used to treat HIV and may also be effective against HBV. The purpose of this study is to find out if adding ADV or TDF to a highly active antiretroviral therapy (HAART) regimen that includes 3TC has an effect on HBV infection in patients coinfected with HIV and HBV. The tolerability and safety of these drugs will be examined.

Afección:Fase:
Infecciones por el VIH
Hepatitis B
Fase 2

Detalles del estudio

HBV presents a worldwide health crisis and is difficult to treat when a patient's HBV strain is no longer responsive to 3TC. Given the significant incidence of 3TC-resistant HBV in patients receiving this drug as part of an antiretroviral regimen, other agents with anti-HBV activity are needed. ADV has shown promising anti-HBV activity in preclinical assessments and in Phase I, II, and III clinical trials. TDF, developed for the treatment of HIV infection, has in vitro activity against HBV. This study will compare TDF/3TC combination therapy with ADV/3TC combination therapy to determine which treatment regimen is more effective in patients coinfected with HBV and HIV.



This study will include two populations of patients. Patients in Population A are on stable HAART that includes TDF and will either be in Group I (compensated liver disease) or Group II (decompensated liver disease). All patients in Population A will be randomly assigned to one of two arms: Arm 1 patients will receive 10 mg ADV daily and TDF placebo; Arm 2 patients will receive ADV placebo and 300 mg TDF. Patients in Population B are on stable HAART and have never taken TDF as part of their HAART. Population B patients will receive 300 mg TDF daily during the course of the study.



Study visits will occur every 4 weeks for the 96-week study period. Targeted clinical and medication assessments and blood work assessing clotting time, liver function, and blood chemistry will be conducted at each study visit. HIV and HBV DNA viral load will be tested every 12 weeks. CD4 cell counts will be tested at Weeks 24, 48, 72, and 96.HBV presents a worldwide health crisis and is difficult to treat when a patient's HBV strain is no longer responsive to 3TC. Given the significant incidence of 3TC-resistant HBV in patients receiving this drug as part of an antiretroviral regimen, other agents with anti-HBV activity are needed. ADV has shown promising anti-HBV activity in preclinical assessments and in Phase I, II, and III clinical trials. TDF, developed for the treatment of HIV infection, has in vitro activity against HBV. This study will compare TDF/3TC combination therapy with ADV/3TC combination therapy to determine which treatment regimen is more effective in patients coinfected with HBV and HIV.



This study will include two populations of patients. Patients in Population A are on stable HAART that includes TDF and will either be in Group I (compensated liver disease) or Group II (decompensated liver disease). All patients in Population A will be randomly assigned to one of two arms: Arm 1 patients will receive 10 mg ADV daily and TDF placebo; Arm 2 patients will receive ADV placebo and 300 mg TDF. Patients in Population B are on stable HAART and have never taken TDF as part of their HAART. Population B patients will receive 300 mg TDF daily during the course of the study.



Study visits will occur every 4 weeks for the 96-week study period. Targeted clinical and medication assessments and blood work assessing clotting time, liver function, and blood chemistry will be conducted at each study visit. HIV and HBV DNA viral load will be tested every 12 weeks. CD4 cell counts will be tested at Weeks 24, 48, 72, and 96.

Criterios de inclusión

    for All Participants:
    • HIV infected
    • HBV infected
    • Serum HBV DNA of 100,000 copies/ml or greater
    • Positive for serum hepatitis B surface antigen (HBsAg) within 12 weeks prior to study entry
    • Agree to use acceptable methods of contraception
    • Serum alpha-fetoprotein (AFP) of 50 ng/ml or less within 30 days of study entry. If AFP is greater than 50 ng/ml, the patient must have an imaging study of the liver showing no tumor within 30 days prior to study entry
    for Population A:
    • Uninterrupted stable HAART regimen at study entry for at least 12 continuous weeks prior to study entry
    • HIV viral load of 10,000 copies/ml or less within 12 weeks of study entry
    for Population A, Group I:
    • Compensated liver disease
    • Child-Pugh-Turcotte (CPT) score of less than 7

Criterios de exclusión

    for Population A, Group I:
    • Excess fluid in the space between the membranes lining the abdomen and abdominal organs (ascites)
    • Gastrointestinal (variceal) bleeding
    • Brain and nervous system damage as a result of liver disease
    • Abnormal blood clotting time
    Inclusion Criteria for Population A, Group II:
    • Decompensated liver disease
    • CPT score of 7-12
    Inclusion Criteria for Population B:
    • Prior HAART regimen
    • Never taken TDF as part of HAART regimen
    • Serum HBV DNA of 100,000 copies/ml or greater within 12 weeks of study entry
    • HIV viral load of greater than 10,000 copies/ml within 12 weeks of study entry
    • CPT score less than 13

Centros de estudio/contactos

California

    UC Davis Medical Center, Sacramento, California, 95814, United States

    Univ. of California Davis Med. Ctr., ACTU, Sacramento, California, 95814, United States

    Ucsf Aids Crs, San Francisco, California, 94110, United States

Colorado

    University of Colorado Hospital CRS, Aurora, Colorado, 80262, United States

Illinois

    Northwestern University CRS, Chicago, Illinois, 60611, United States

    Cook County Hosp. CORE Ctr., Chicago, Illinois, 60612, United States

Maryland

    Johns Hopkins Adult AIDS CRS, Baltimore, Maryland, 21287, United States

New York

    Beth Israel Med. Ctr., ACTU, New York, New York, 10003, United States

    NY Univ. HIV/AIDS CRS, New York, New York, 10016, United States

    Cornell CRS, New York, New York, 10021, United States

    Weill Med. College of Cornell Univ., The Cornell CTU, New York, New York, 10021, United States

Ohio

    Univ. of Cincinnati CRS, Cincinnati, Ohio, 452670405, United States

    MetroHealth CRS, Cleveland, Ohio, 441091998, United States

Tennessee

    Vanderbilt Therapeutics CRS, Nashville, Tennessee, 37203, United States

Washington

    University of Washington AIDS CRS, Seattle, Washington, 98104, United States

Actualizado: 13 de octubre del 2004

Volver arriba